Abstract
Purpose
Metformin has been used clinically for more than six decades. Over time, numerous remarkable effects of metformin beyond the clinic have been discovered and discussed. Metformin has been shown to have a favorable impact on cancer therapy in addition to its clinically recognized hypoglycemic effect. However, the antitumor efficacy of metformin in humans has not been clearly demonstrated yet. Hence, a systematic analysis of the existing trials is necessary.
Methods
Here, we retrieved clinical trials from the Clinical Trials.gov database to overview the clinical development of metformin for the treatment of cancer, analyze existing clinical results, and summarize some promising applications for specific cancer therapies.
Results
The potential application of metformin contains three directions: Firstly, improvement of metabolic factors associated with treatment effects, such as insulin resistance and peripheral neuropathy. Secondly, in combination with immune checkpoint blockade effects. Finally, use it for the endocrine treatment of hormone-dependent cancers.
Conclusion
Although the outcomes of metformin as a repurposed agent in some trials have been unsatisfactory, it still has the potential to be used in select cancer therapy settings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that supports the findings of this study are openly available in ClinicalTrials.gov at https://clinicaltrials.gov/.
References
Afzal MZ, Mercado RR, Shirai K (2018) Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. J ImmunoTher Cancer. https://doi.org/10.1186/s40425-018-0375-1
Afzal MZ, Dragnev K, Sarwar T, Shirai K (2019) Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manag 8(2):Lmt11. https://doi.org/10.2217/lmt-2018-0016
Al Hassan M, Fakhoury I, El Masri Z, Ghazale N, Dennaoui R, El Atat O, Kanaan A, El-Sibai M (2018) Metformin treatment inhibits motility and invasion of glioblastoma cancer cells. Anal Cell Pathol (amst) 2018:5917470. https://doi.org/10.1155/2018/5917470
Alghandour R, Ebrahim MA, Elshal AM, Ghobrial F, Elzaafarany M (2021) Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED). Urol Oncol 39(12):831 e831-831 e810. https://doi.org/10.1016/j.urolonc.2021.05.020
Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M (2008) Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15(3):833–839. https://doi.org/10.1677/erc-08-0038
Alipour S, Abedi M, Saberi A, Maleki-Hajiagha A, Faiz F, Shahsavari S, Eslami B (2021) Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial. BMC Endocr Disord 21(1):169. https://doi.org/10.1186/s12902-021-00824-4
Amaral MEA, Nery LR, Leite CE, de Azevedo Junior WF, Campos MM (2018) Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Invest New Drugs 36(5):782–796. https://doi.org/10.1007/s10637-018-0568-y
Amin D, Richa T, Mollaee M, Zhan T, Tassone P, Johnson J, Luginbuhl A, Cognetti D, Martinez-Outschoorn U, Stapp R, Solomides C, Rodeck U, Curry J (2020) Metformin effects on FOXP3(+) and CD8(+) T cell infiltrates of head and neck squamous cell carcinoma. Laryngoscope 130(9):E490–E498. https://doi.org/10.1002/lary.28336
Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Blery M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E (2018) Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175(7):1731-1743 e1713. https://doi.org/10.1016/j.cell.2018.10.014
Arrieta O, Varela-Santoyo E, Soto-Perez-de-Celis E, Sanchez-Reyes R, De la Torre-Vallejo M, Muniz-Hernandez S, Cardona AF (2016) Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer. BMC Cancer 16:633. https://doi.org/10.1186/s12885-016-2658-6
Arrieta O, Barron F, Padilla MS, Aviles-Salas A, Ramirez-Tirado LA, Arguelles Jimenez MJ, Vergara E, Zatarain-Barron ZL, Hernandez-Pedro N, Cardona AF, Cruz-Rico G, Barrios-Bernal P, Yamamoto Ramos M, Rosell R (2019) Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 5(11):e192553. https://doi.org/10.1001/jamaoncol.2019.2553
Barakat HE, Hussein RRS, Elberry AA, Zaki MA, Ramadan ME (2022) The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. Sci Rep 12(1):7656. https://doi.org/10.1038/s41598-022-11138-3
Belardi V, Gallagher EJ, Novosyadlyy R, LeRoith D (2013) Insulin and IGFs in obesity-related breast cancer. J Mammary Gland Biol Neoplasia 18(3–4):277–289. https://doi.org/10.1007/s10911-013-9303-7
Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25):3576–3586. https://doi.org/10.1038/sj.onc.1211024
Bilusic M, Toney NJ, Donahue RN, Wroblewski S, Zibelman M, Ghatalia P, Ross EA, Karzai F, Madan RA, Dahut WL, Gulley JL, Schlom J, Plimack ER, Geynisman DM (2022) A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer Prostatic Dis 25(4):735–740. https://doi.org/10.1038/s41391-022-00492-y
Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30(21):2593–2600. https://doi.org/10.1200/JCO.2011.39.3769
Boucaud-Maitre D, Ropers J, Porokhov B, Altman JJ, Bouhanick B, Doucet J, Girardin E, Kaloustian E, Lassmann Vague V, Emmerich J (2016) Lactic acidosis: relationship between metformin levels, lactate concentration and mortality. Diabet Med 33(11):1536–1543. https://doi.org/10.1111/dme.13098
Broadfield LA, Saigal A, Szamosi JC, Hammill JA, Bezverbnaya K, Wang D, Gautam J, Tsakiridis EE, Di Pastena F, McNicol J, Wu J, Syed S, Lally JSV, Raphenya AR, Blouin MJ, Pollak M, Sacconi A, Blandino G, McArthur AG, Schertzer JD, Surette MG, Collins SM, Bramson JL, Muti P, Tsakiridis T, Steinberg GR (2022) Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. Mol Metab 61:101498. https://doi.org/10.1016/j.molmet.2022.101498
Cai D, Sun H, Qi Y, Zhao X, Feng M, Wu X (2016) Insulin-like growth factor 1/mammalian target of rapamycin and AMP-activated protein kinase signaling involved in the effects of metformin in the human endometrial cancer. Int J Gynecol Cancer 26(9):1667–1672. https://doi.org/10.1097/IGC.0000000000000818
Cai Z, Li C-F, Han F, Liu C, Zhang A, Hsu C-C, Peng D, Zhang X, Jin G, Rezaeian A-H, Wang G, Zhang W, Pan B-S, Wang C-Y, Wang Y-H, Wu S-Y, Yang S-C, Hsu F-C, D’Agostino RB, Furdui CM, Kucera GL, Parks JS, Chilton FH, Huang C-Y, Tsai F-J, Pasche B, Watabe K, Lin H-K (2020) Phosphorylation of PDHA by AMPK drives TCA cycle to promote cancer metastasis. Mol Cell 80(2):263-278.e267. https://doi.org/10.1016/j.molcel.2020.09.018
Campagnoli C, Pasanisi P, Abba C, Ambroggio S, Biglia N, Brucato T, Colombero R, Danese S, Donadio M, Venturelli E, Zito G, Berrino F (2012) Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer 12(3):175–182. https://doi.org/10.1016/j.clbc.2012.03.004
Campagnoli C, Berrino F, Venturelli E, Abbà C, Biglia N, Brucato T, Cogliati P, Danese S, Donadio M, Zito G, Pasanisi P (2013) Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer 13(6):433–438. https://doi.org/10.1016/j.clbc.2013.08.012
Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL (2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation–implications for a novel treatment strategy. Gynecol Oncol 116(1):92–98. https://doi.org/10.1016/j.ygyno.2009.09.024
Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell’Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B (2013) The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 109(11):2792–2797. https://doi.org/10.1038/bjc.2013.657
Cheng FJ, Chen CH, Tsai WC, Wang BW, Yu MC, Hsia TC, Wei YL, Hsiao YC, Hu DW, Ho CY, Li TS, Wu CY, Chou WY, Yu YL, Tang CH, Chen CY, Chen CM, Hsu JL, Chen HF, Chen Y, Tu CY, Hung MC, Huang WC (2021) Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC. Oncogene 40(6):1162–1175. https://doi.org/10.1038/s41388-020-01597-1
Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O’Brien K, Wang Y, Hilakivi-Clarke LA (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22(47):7316–7339. https://doi.org/10.1038/sj.onc.1206937
Coyle C, Cafferty FH, Vale C, Langley RE (2016) Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 27(12):2184–2195. https://doi.org/10.1093/annonc/mdw410
Crist M, Yaniv B, Palackdharry S, Lehn MA, Medvedovic M, Stone T, Gulati S, Karivedu V, Borchers M, Fuhrman B, Crago A, Curry J, Martinez-Outschoorn U, Takiar V, Wise-Draper TM (2022) Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition. J Immunother Cancer. https://doi.org/10.1136/jitc-2022-005632
DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN (2014) Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 148(1):81–90. https://doi.org/10.1007/s10549-014-3141-1
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, Pruneri G (2015) Effect of metformin on breast ductal carcinoma in situ proliferation in a randomized presurgical trial. Cancer Prev Res (phila) 8(10):888–894. https://doi.org/10.1158/1940-6207.CAPR-15-0048
Dowling RJ, Niraula S, Chang MC, Done SJ, Ennis M, McCready DR, Leong WL, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V (2015) Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res 17(1):32. https://doi.org/10.1186/s13058-015-0540-0
Eichner LJ, Brun SN, Herzig S, Young NP, Curtis SD, Shackelford DB, Shokhirev MN, Leblanc M, Vera LI, Hutchins A, Ross DS, Shaw RJ, Svensson RU (2019) Genetic analysis reveals AMPK is required to support tumor growth in murine Kras-dependent lung cancer models. Cell Metab 29(2):285-302.e287. https://doi.org/10.1016/j.cmet.2018.10.005
El-Fatatry BM, Ibrahim OM, Hussien FZ, Mostafa TM (2018) Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. Int J Colorectal Dis 33(12):1675–1683. https://doi.org/10.1007/s00384-018-3104-9
Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. JNCI: J Natl Cancer Institute 98(19):1406–1415. https://doi.org/10.1093/jnci/djj376
Emons G (2022) Hormone-dependent cancers: molecular mechanisms and therapeutical implications. Cells. https://doi.org/10.3390/cells12010110
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304–1305. https://doi.org/10.1136/bmj.38415.708634.F7
Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120(7):2355–2369. https://doi.org/10.1172/jci40671
Gallagher EJ, LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21(10):610–618. https://doi.org/10.1016/j.tem.2010.06.007
Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery 18(3):197–218. https://doi.org/10.1038/s41573-018-0007-y
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103(6):491–497. https://doi.org/10.1016/s0002-9343(97)00254-4
Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51. https://doi.org/10.1200/jco.2002.20.1.42
Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8(6):501–505. https://doi.org/10.3816/CBC.2008.n.060
Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V (2015) Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv006
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR (2022) Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: The MA.32 randomized clinical trial. JAMA 327(20):1963–1973. https://doi.org/10.1001/jama.2022.6147
Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81–98. https://doi.org/10.2165/11534750-000000000-00000
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101(1):48–60. https://doi.org/10.1093/jnci/djn415
Hadad SM, Coates P, Jordan LB, Dowling RJ, Chang MC, Done SJ, Purdie CA, Goodwin PJ, Stambolic V, Moulder-Thompson S, Thompson AM (2015) Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Res Treat 150(1):149–155. https://doi.org/10.1007/s10549-015-3307-5
Han F, Li C-F, Cai Z, Zhang X, Jin G, Zhang W-N, Xu C, Wang C-Y, Morrow J, Zhang S, Xu D, Wang G, Lin H-K (2018) The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun. https://doi.org/10.1038/s41467-018-07188-9
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567. https://doi.org/10.1038/nature14011
Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ (2012) Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control. Diabetes Care 35(2):446–454. https://doi.org/10.2337/dc11-1465
Hsu C-C, Peng D, Cai Z, Lin H-K (2022) AMPK signaling and its targeting in cancer progression and treatment. Semin Cancer Biol 85:52–68. https://doi.org/10.1016/j.semcancer.2021.04.006
Huang X, Hong X, Wang J, Sun T, Yu T, Yu Y, Fang J, Xiong H (2020) Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis. EBioMedicine 61:103037. https://doi.org/10.1016/j.ebiom.2020.103037
Hunter RW, Hughey CC, Lantier L, Sundelin EI, Peggie M, Zeqiraj E, Sicheri F, Jessen N, Wasserman DH, Sakamoto K (2018) Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat Med 24(9):1395–1406. https://doi.org/10.1038/s41591-018-0159-7
Indraccolo S, Randon G, Zulato E, Nardin M, Aliberti C, Pomerri F, Casarin A, Nicoletto MO (2015) Metformin: a modulator of bevacizumab activity in cancer? A case report. Cancer Biol Ther 16(2):210–214. https://doi.org/10.1080/15384047.2014.1002366
Irwin ML, McTiernan A, Bernstein L, Gilliland FD, Baumgartner R, Baumgartner K, Ballard-Barbash R (2005) Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors. Cancer Epidemiol Biomarkers Prev 14(12):2881–2888. https://doi.org/10.1158/1055-9965.Epi-05-0185
Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, Walker G, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A (2021) Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecol Oncol 161(1):143–151. https://doi.org/10.1016/j.ygyno.2021.01.029
Jeon S-M, Chandel NS, Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485(7400):661–665. https://doi.org/10.1038/nature11066
Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, van der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J, Pollak M (2014) A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17(3):252–258. https://doi.org/10.1038/pcan.2014.20
Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12(4):1071–1082. https://doi.org/10.1677/erc.1.01038
Kajbaf F, Lalau J-D (2014) Mortality rate in so-called “metformin-associated lactic acidosis”: a review of the data since the 1960s. Pharmacoepidemiol Drug Saf 23(11):1123–1127. https://doi.org/10.1002/pds.3689
Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11(5):390–401. https://doi.org/10.1016/j.cmet.2010.03.014
Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, Taback B, Ahmad A, Cremers S, Hibshoosh H, Maurer M, Hershman DL (2014) Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 32(4):150–157. https://doi.org/10.3109/07357907.2014.889706
Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57(2):205–212. https://doi.org/10.1038/bjc.1988.44
Kim TH, Franco HL, Jung SY, Qin J, Broaddus RR, Lydon JP, Jeong JW (2010) The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene 29(26):3770–3780. https://doi.org/10.1038/onc.2010.126
Kishton Rigel J, Barnes Carson E, Nichols Amanda G, Cohen S, Gerriets Valerie A, Siska Peter J, Macintyre Andrew N, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes Marc O, Abel ED, Yeoh Allen Eng J, Gershon Timothy R, Rathmell WK, Richards Kristy L, Locasale Jason W, Rathmell Jeffrey C (2016) AMPK is essential to balance glycolysis and mitochondrial metabolism to control T-all cell stress and survival. Cell Metab 23(4):649–662. https://doi.org/10.1016/j.cmet.2016.03.008
Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton PW, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ (2019) PRE-surgical metformin in uterine malignancy (PREMIUM): a multi-center, randomized double-blind, placebo-controlled phase III trial. Clin Cancer Res 25(8):2424–2432. https://doi.org/10.1158/1078-0432.CCR-18-3339
Kong WY, Liu ZA, Zhang N, Wu X, Zhao XB, Yan L (2022) A prospective cohort study of metformin as an adjuvant therapy for infertile women with endometrial complex hyperplasia/complex atypical hyperplasia and their subsequent assisted reproductive technology outcomes. Front Endocrinol (Lausanne) 13:849794. https://doi.org/10.3389/fendo.2022.849794
Lalau JD, Lemaire-Hurtel AS, Lacroix C (2011) Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig 31(6):435–438. https://doi.org/10.2165/11588310-000000000-00000
Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH (2014) Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 134(3):607–614. https://doi.org/10.1016/j.ygyno.2014.06.014
Lee Y, Joo J, Lee YJ, Lee EK, Park S, Kim TS, Lee SH, Kim SY, Wie GA, Park M, Kim MJ, Lee JS, Han JY (2021) Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. Lung Cancer 151:8–15. https://doi.org/10.1016/j.lungcan.2020.11.011
Li L, Jiang L, Wang Y, Zhao Y, Zhang XJ, Wu G, Zhou X, Sun J, Bai J, Ren B, Tian K, Xu Z, Xiao HL, Zhou Q, Han R, Chen H, Wang H, Yang Z, Gao C, Cai S, He Y (2019) Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced NSCLC patients with EGFR mutations: a randomized, double-blind phase ii trial. Clin Cancer Res 25(23):6967–6975. https://doi.org/10.1158/1078-0432.CCR-19-0437
Liu YT, Sun ZJ (2021) Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11(11):5365–5386. https://doi.org/10.7150/thno.58390
Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR (2013) Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (phila) 6(8):774–781. https://doi.org/10.1158/1940-6207.CAPR-13-0020
Ma T, Tian X, Zhang B, Li M, Wang Y, Yang C, Wu J, Wei X, Qu Q, Yu Y, Long S, Feng JW, Li C, Zhang C, Xie C, Wu Y, Xu Z, Chen J, Yu Y, Huang X, He Y, Yao L, Zhang L, Zhu M, Wang W, Wang ZC, Zhang M, Bao Y, Jia W, Lin SY, Ye Z, Piao HL, Deng X, Zhang CS, Lin SC (2022) Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature 603(7899):159–165. https://doi.org/10.1038/s41586-022-04431-8
Ma L, Wei J, Wan J, Wang W, Wang L, Yuan Y, Yang Z, Liu X, Ming L (2019) Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Experim Clin Cancer Res. https://doi.org/10.1186/s13046-019-1090-6
Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R (2019) Impact of addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (MetAb-Pro): phase 2 pilot study. Clin Genitourin Cancer 17(2):e323–e328. https://doi.org/10.1016/j.clgc.2018.12.009
Marrone KA, Zhou X, Forde PM, Purtell M, Brahmer JR, Hann CL, Kelly RJ, Coleman B, Gabrielson E, Rosner GL, Ettinger DS (2018) A randomized Phase II study of metformin plus paclitaxel/carboplatin/bevacizumab in patients with chemotherapy-naive advanced or metastatic nonsquamous non-small cell lung cancer. Oncologist 23(7):859–865. https://doi.org/10.1634/theoncologist.2017-0465
McNamara K, Isbister GK (2015) Hyperlactataemia and clinical severity of acute metformin overdose. Intern Med J 45(4):402–408. https://doi.org/10.1111/imj.12713
Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M (2014) Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 120(19):2986–2995. https://doi.org/10.1002/cncr.28853
Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M (2016) Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol 27(2):262–266. https://doi.org/10.1093/annonc/mdv539
Morales DR, Morris AD (2015) Metformin in cancer treatment and prevention. Annu Rev Med 66:17–29. https://doi.org/10.1146/annurev-med-062613-093128
Morgillo F, Fasano M, Della Corte CM, Sasso FC, Papaccio F, Viscardi G, Esposito G, Di Liello R, Normanno N, Capuano A, Berrino L, Vicidomini G, Fiorelli A, Santini M, Ciardiello F (2017) Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. ESMO Open 2(2):e000132. https://doi.org/10.1136/esmoopen-2016-000132
Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, Gianni L, Rosetti F, Amaducci L, Cavanna L, Foca F, Sarti S, Serra P, Valmorri L, Bruzzi P, Corradengo D, Gennari A, investigators M (2019) Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Res Treat 174(2):433–442. https://doi.org/10.1007/s10549-018-05070-2
Nguyen MM, Martinez JA, Hsu CH, Sokoloff M, Krouse RS, Gibson BA, Nagle RB, Parnes HL, Cordova C, Chow HS (2018) Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort. Eur J Cancer Prev 27(6):557–562. https://doi.org/10.1097/CEJ.0000000000000394
Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA, Kurshan N, Mejia W, Santopietro S, Yakar S, Wood TL, LeRoith D (2010) Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70(2):741–751. https://doi.org/10.1158/0008-5472.CAN-09-2141
Nurgali K, Jagoe RT, Abalo R (2018) Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol 9:245. https://doi.org/10.3389/fphar.2018.00245
Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 Pt 3(Pt 3):607–614
Pabona JMP, Burnett AF, Brown DM, Quick CM, Simmen FA, Montales MTE, Liu SJ, Rose T, Alhallak I, Siegel ER, Simmen RC (2020) Metformin promotes anti-tumor biomarkers in human endometrial cancer cells. Reprod Sci 27(1):267–277. https://doi.org/10.1007/s43032-019-00019-2
Parikh AB, Kozuch P, Rohs N, Becker DJ, Levy BP (2017) Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. Invest New Drugs 35(6):813–819. https://doi.org/10.1007/s10637-017-0511-7
Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119(1):236–238. https://doi.org/10.1002/ijc.21812
Payne H, Robinson A, Rappe B, Hilman S, De Giorgi U, Joniau S, Bordonaro R, Mallick S, Dourthe LM, Flores MM, Guma J, Baron B, Duran A, Pranzo A, Serikoff A, Mott D, Herdman M, Pavesi M, De Santis M (2022) A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. Int J Cancer 150(5):837–846. https://doi.org/10.1002/ijc.33845
Pernicova I, Korbonits M (2014) Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10(3):143–156. https://doi.org/10.1038/nrendo.2013.256
Petchsila K, Prueksaritanond N, Insin P, Yanaranop M, Chotikawichean N (2020) Effect of metformin for decreasing proliferative marker in women with endometrial cancer: a randomized double-blind placebo-controlled trial. Asian Pac J Cancer Prev 21(3):733–741. https://doi.org/10.31557/APJCP.2020.21.3.733
Pimentel I, Lohmann AE, Ennis M, Dowling RJO, Cescon D, Elser C, Potvin KR, Haq R, Hamm C, Chang MC, Stambolic V, Goodwin PJ (2019) A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast 48:17–23. https://doi.org/10.1016/j.breast.2019.08.003
Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I, Hobday T, Lemieux J, Thompson A, Rastogi P, Gelmon K, Rea D, Rabaglio M, Ellard S, Mates M, Bedard P, Pitre L, Vandenberg T, Dowling RJO, Parulekar W, Goodwin PJ (2021) The effect of metformin vs placebo on sex hormones in canadian cancer trials group MA.32. J Natl Cancer Inst 113(2):192–198. https://doi.org/10.1093/jnci/djaa082
Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12(3):159–169. https://doi.org/10.1038/nrc3215
Quaile MP, Melich DH, Jordan HL, Nold JB, Chism JP, Polli JW, Smith GA, Rhodes MC (2010) Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol 243(3):340–347. https://doi.org/10.1016/j.taap.2009.11.026
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA (2013) Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 24(9):469–480. https://doi.org/10.1016/j.tem.2013.05.004
Rattan R, Giri S, Hartmann LC, Shridhar V (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15(1):166–178. https://doi.org/10.1111/j.1582-4934.2009.00954.x
Raza U, Sheikh A, Jamali SN, Turab M, Zaidi SA, Jawaid H (2020) Post-treatment hematological variations and the role of hemoglobin as a predictor of disease-free survival in stage 2 breast cancer patients. Cureus 12(3):e7259. https://doi.org/10.7759/cureus.7259
Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, Pollak M, Lui L, Endt K, Schiess R, Ruschoff JH, Cathomas R, Gillessen S (2014) Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol 66(3):468–474. https://doi.org/10.1016/j.eururo.2013.12.057
Saif MW, Rajagopal S, Caplain J, Grimm E, Serebrennikova O, Das M, Tsichlis PN, Martell R (2019) A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors. Cancer Chemother Pharmacol 84(6):1323–1331. https://doi.org/10.1007/s00280-019-03967-3
Saito Y, Chapple Richard H, Lin A, Kitano A, Nakada D (2015) AMPK protects leukemia-initiating cells in myeloid leukemias from metabolic stress in the bone marrow. Cell Stem Cell 17(5):585–596. https://doi.org/10.1016/j.stem.2015.08.019
Sangha R, Davies AM, Lara PN Jr, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR (2011) Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol 6(12):2112–2119. https://doi.org/10.1097/JTO.0b013e31822ae061
Sayed R, Saad AS, El Wakeel L, Elkholy E, Badary O (2015) Metformin addition to chemotherapy in stage IV non-small cell lung cancer: an open label randomized controlled study. Asian Pac J Cancer Prev 16(15):6621–6626. https://doi.org/10.7314/apjcp.2015.16.15.6621
Sharma LK, Lu J, Bai Y (2009) Mitochondrial respiratory complex I: structure, function and implication in human diseases. Curr Med Chem 16(10):1266–1277. https://doi.org/10.2174/092986709787846578
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708
Siiteri PK (1978) Steroid hormones and endometrial cancer. Cancer Res 38(11 Pt 2):4360–4366
Silvestre J, Carvalho S, Mendes V, Coelho L, Tapadinhas C, Ferreira P, Povoa P, Ceia F (2007) Metformin-induced lactic acidosis: a case series. J Med Case Rep 1:126. https://doi.org/10.1186/1752-1947-1-126
Sivalingam VN, Kitson S, McVey R, Roberts C, Pemberton P, Gilmour K, Ali S, Renehan AG, Kitchener HC, Crosbie EJ (2016) Measuring the biological effect of presurgical metformin treatment in endometrial cancer. Br J Cancer 114(3):281–289. https://doi.org/10.1038/bjc.2015.453
Skinner H, Hu C, Tsakiridis T, Santana-Davila R, Lu B, Erasmus JJ, Doemer AJ, Videtic GMM, Coster J, Yang AX, Lee RY, Werner-Wasik M, Schaner PE, McCormack SE, Esparaz BT, McGarry RC, Bazan J, Struve T, Paulus R, Bradley JD (2021) Addition of metformin to concurrent chemoradiation in patients with locally advanced non-small cell lung cancer: The NRG-LU001 phase 2 randomized clinical trial. JAMA Oncol 7(9):1324–1332. https://doi.org/10.1001/jamaoncol.2021.2318
Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E (2017) Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALTTO Phase III randomized trial. J Clin Oncol 35(13):1421–1429. https://doi.org/10.1200/JCO.2016.69.7722
Stepensky D, Friedman M, Raz I, Hoffman A (2002) Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 30(8):861–868. https://doi.org/10.1124/dmd.30.8.861
Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang C (2018) Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 24(12):1919–1929. https://doi.org/10.1038/s41591-018-0222-4
Tang G, Guo J, Zhu Y, Huang Z, Liu T, Cai J, Yu L, Wang Z (2018) Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation. Int J Oncol 52(6):1899–1911. https://doi.org/10.3892/ijo.2018.4343
Tsakiridis T, Pond GR, Wright J, Ellis PM, Ahmed N, Abdulkarim B, Roa W, Robinson A, Swaminath A, Okawara G, Wierzbicki M, Valdes M, Levine M (2021) Metformin in combination with chemoradiotherapy in locally advanced non-small cell lung cancer: The OCOG-ALMERA randomized clinical trial. JAMA Oncol 7(9):1333–1341. https://doi.org/10.1001/jamaoncol.2021.2328
van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR (2007) Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 120(9):1986–1992. https://doi.org/10.1002/ijc.22532
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM (2008) Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 14(47):7192–7198. https://doi.org/10.3748/wjg.14.7192
Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, Chen S, Wang G, Lin P, Chen H, Yeung SJ, Bremer E, Zhang H (2020) Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial. Clin Cancer Res 26(18):4921–4932. https://doi.org/10.1158/1078-0432.CCR-20-0113
Wilson BE, Armstrong AJ, de Bono J, Sternberg CN, Ryan CJ, Scher HI, Smith MR, Rathkopf D, Logothetis CJ, Chi KN, Jones RJ, Saad F, De Porre P, Tran N, Hu P, Gillessen S, Carles J, Fizazi K, Joshua AM (2022) Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. Eur J Cancer 170:296–304. https://doi.org/10.1016/j.ejca.2022.03.042
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, Stahlman M, Olsson LM, Serino M, Planas-Felix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernandez-Real JM, Backhed F (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23(7):850–858. https://doi.org/10.1038/nm.4345
Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86(3):s823-835. https://doi.org/10.1093/ajcn/86.3.823S
Yang BY, Gulinazi Y, Du Y, Ning CC, Cheng YL, Shan WW, Luo XZ, Zhang HW, Zhu Q, Ma FH, Liu J, Sun L, Yu M, Guan J, Chen XJ (2020) Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG 127(7):848–857. https://doi.org/10.1111/1471-0528.16108
Yeh HC, Maruthur NM, Wang NY, Jerome GJ, Dalcin AT, Tseng E, White K, Miller ER, Juraschek SP, Mueller NT, Charleston J, Durkin N, Hassoon A, Lansey DG, Kanarek NF, Carducci MA, Appel LJ (2021) Effects of behavioral weight loss and metformin on IGFs in cancer survivors: a randomized trial. J Clin Endocrinol Metab 106(10):e4179–e4191. https://doi.org/10.1210/clinem/dgab266
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66(21):10269–10273. https://doi.org/10.1158/0008-5472.Can-06-1500
Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (phila) 1(5):369–375. https://doi.org/10.1158/1940-6207.Capr-08-0081
Acknowledgements
This work was supported by the National Natural Science Foundation of China (Grant No. 82000808).
Funding
This study was funded by the National Natural Science Foundation of China (82000808).
Author information
Authors and Affiliations
Contributions
L.W. conceived the manuscript. Z.W., W.W. and L.W. wrote the manuscript. S.Z. contributed to critical discussion. All authors reviewed the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wu, Z., Wang, W., Wei, L. et al. Current status and frontier tracking of clinical trials on Metformin for cancer treatment. J Cancer Res Clin Oncol 149, 16931–16946 (2023). https://doi.org/10.1007/s00432-023-05391-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05391-w